![Valerie Anderson](https://profiles-cardiff.imgix.net/attachments/616?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Valerie Anderson
Timau a rolau for Valerie Anderson
Cynorthwy-ydd Ymchwil, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
Trosolwg
Rwy'n cyfrannu at ymchwil sy'n ymchwilio i'r diagnosis, y cynnydd a'r canlyniadau mewn sglerosis ymledol. Mae fy rôl yn cynnwys cydlynu lleol ar gyfer nifer o dreialon clinigol mewn sglerosis ymledol. Mae gennyf ddiddordeb hefyd mewn cyfranogiad cleifion a'r cyhoedd yn natblygiad ymchwil mewn sglerosis ymledol.
Cyhoeddiad
2025
- Kremler, C. et al., 2025. Real world outcomes of alemtuzumab in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 96 , pp.A42.3. (10.1136/jnnp-2025-ABN.139)
2024
- Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31 (7) e16289. (10.1111/ene.16289)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
2023
- Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
2022
- Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64 103937. (10.1016/j.msard.2022.103937)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)
2020
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
2018
- Beesley, R. et al., 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24 (13), pp.1786-1787. (10.1177/1352458518778007)
- Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25 , pp.186-191. (10.1016/j.msard.2018.08.001)
Erthyglau
- Kremler, C. et al., 2025. Real world outcomes of alemtuzumab in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 96 , pp.A42.3. (10.1136/jnnp-2025-ABN.139)
- Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31 (7) e16289. (10.1111/ene.16289)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
- Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64 103937. (10.1016/j.msard.2022.103937)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
- Beesley, R. et al., 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24 (13), pp.1786-1787. (10.1177/1352458518778007)
- Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25 , pp.186-191. (10.1016/j.msard.2018.08.001)
Contact Details
[email protected]
Prif Adeilad yr Ysbyty, Ystafell Ystafell 80G, 4ydd llawr B-C Coridor Cyswllt, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Prif Adeilad yr Ysbyty, Ystafell Ystafell 80G, 4ydd llawr B-C Coridor Cyswllt, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN